BLAINJECTIONINJECTABLE
Approved
Dec 2017
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
OGIVRI (trastuzumab-dkst) by Viatris (2) is her2/neu/cerbb2 antagonists [moa]. Approved for breast cancer, metastatic breast cancer, her2-positive breast cancer and 1 more indications. First approved in 2017.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OGIVRI (trastuzumab-dkst) is a monoclonal antibody biosimilar that targets HER2/neu receptors on cancer cells, approved as a biosimilar to Herceptin. It is indicated for HER2-positive breast cancer and multiple solid tumors including gastric, lung, and ovarian cancers. The drug works by binding to HER2 receptors and blocking growth signaling in HER2-overexpressing tumors.
$0.822MPart D
PeakOGIVRI is in peak lifecycle with minimal Part D spending ($822K), indicating limited penetration as a biosimilar in the high-volume HER2+ oncology market dominated by branded trastuzumab.
Mechanism of Action
HER2/Neu/cerbB2 Antagonists
Pharmacologic Class:
HER2/neu Receptor Antagonist
Indications (4)
Worked on OGIVRI at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.